Paradox breaker BRAF inhibitors have comparable potency and MAPK pathway reactivation to encorafenib in BRAF mutant colorectal cancer

The BEACON CRC trial demonstrated a survival advantage over chemotherapy for a combination of targeted agents comprising the potent BRAF inhibitor encorafenib together with cetuximab and binimetinib. Resistance to BRAF inhibition in CRC arises in part through the generation and activation of RAF dim...

Descripción completa

Detalles Bibliográficos
Autores principales: Pickles, Oliver J., Drozd, Aneta, Tee, Louise, Beggs, Andrew D., Middleton, Gary W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2020
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7456617/
https://www.ncbi.nlm.nih.gov/pubmed/32922659
http://dx.doi.org/10.18632/oncotarget.27681

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7456617/
https://www.ncbi.nlm.nih.gov/pubmed/32922659
http://dx.doi.org/10.18632/oncotarget.27681

Ejemplares similares